Day One

• Integrating artificial intelligence, robotics, and high-throughput experimentation to systematically identify productive induced-proximity events, accelerating molecular glue discovery at unprecedented scale
• Leveraging a purpose-built AI infrastructure designed specifically for molecular glue biology to uncover novel target-ligase relationships, expanding the searchable discovery landscape beyond traditional approaches
• Applying large-scale experimental and computational workflows to rapidly generate, validate, and prioritize molecular glue candidates, enabling faster progression from discovery to therapeutic development

• How can AI-powered and computational approaches be used to identify gluable surfaces, target-ligase pairings, and novel molecular glue opportunities, while integrating target selection with the practical challenge of finding tractable gluable interfaces?
• How can the molecular glue field overcome limited datasets to improve model training, predictive accuracy, and biological relevance, enabling more reliable AI-driven discovery workflows?
• How can computational predictions be most effectively combined with experimental screening, structural biology, and validation strategies to accelerate hit identification and optimize molecular glue potency and selectivity?

• Leveraging new platform systematically map target-ligase interactions and identify productive induced-proximity events, expanding access to previously undruggable proteins
• Integrating functional screening, proteomics, and mechanistic profiling to rapidly validate molecular glue hits, improving confidence in target engagement and downstream biological activity
• Applying a target-first discovery strategy to uncover novel degrader opportunities across challenging protein classes, enabling more efficient progression from target selection to therapeutic candidate

Join our speed networking session tailored for Molecular Glue professionals, like yourself, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space.

• Applying DNA-encoded libraries (DELs) to interrogate vast chemical space for rare and productive glue interactions, unlocking novel starting points against challenging targets
• Uncovering unexpected mechanisms of cooperativity in ternary complex formation, leading to higher quality hits and a more efficient discovery process
• Implementing a comprehensive downstream validation workflow to rapidly confirm on-target mechanism and accelerate the progression of validated hits toward lead optimization

• Anchoring hit identification on a highly sensitive, gain-of-signal biochemical proximity assay to maximize early detection of ternary-complex formation, opening a productive front-line screen for undruggable targets defined by weak or transient basal target and ligase interactions

• Sequencing a tiered validation cascade, spanning biochemical proximity, binder competition, functional ubiquitination, and cellular degradation, in which each tier enforces a distinct mechanistic criterion that systematically eliminates proximity-only false positives before committing chemistry resources

• Translating this orthogonally cross-validated funnel into confident go/no-go decisions and a generalizable, plug-and-play discovery framework that is portable across diverse undruggable targets and E3 ligases

• Developing molecular glue degraders that leverage endogenous ligases beyond cereblon, expanding the range of induced-proximity mechanisms available for targeted protein degradation
• Applying novel ligase biology to challenging targets including KRAS and SREBF, unlocking therapeutic opportunities against proteins that have traditionally proven difficult to drug
• Establishing a new framework for molecular glue discovery beyond cereblon-dependent approaches, broadening the degrader toolbox and enabling the next generation of targeted therapies

• Overcoming the field’s reliance on Cereblon-first discovery by developing a target-directed strategy that expands molecular glue opportunities across new biological pathways
• Matching targets to the most suitable ligases through a mutagenesis-based approach, enabling discovery efforts beyond established Cereblon biology
• Building a more systematic framework for molecular glue discovery to uncover novel target-ligase pairings, broaden the druggable proteome, and accelerate first-in-class therapeutic opportunities

Take this opportunity to showcase your latest research and innovations with your peers and understand the strategies of your fellow Molecular Glue experts. Visit the website for the full T&Cs of submitting a poster

• Advancing a novel non-degrading molecular glue from discovery through clinical development, demonstrating how induced-proximity therapeutics can generate therapeutic benefit beyond protein degradation
• Evaluating safety, pharmacokinetics, pharmacodynamic biomarkers, and early signals of activity from first-in-human studies to establish the clinical potential of nondegrading molecular glue therapies
• Sharing key translational and clinical learnings from programme progression to help de-risk future molecular glue development efforts and accelerate the path from innovative biology to patient impact

• How can developers integrate proteomics, mechanistic biology, translational biomarkers, and emerging clinical data to identify safety liabilities early and improve confidence in candidate selection?
• What are the most important scientific, clinical, regulatory, and commercial risks facing molecular glue programmes today, and how should biotech leaders, investors, and drug developers assess them when making development and funding decisions?
• As more molecular glues advance toward the clinic, what frameworks are needed to evaluate off-target effects, long-term biological consequences, and programme differentiation to enable informed go/no-go, partnering, and investment decisions?

• Elucidating thalidomide’s MoA led to realizing the promise of harnessing CRBN for targeted protein degradation
• Structural insight into cereblon ternary complexes is guiding the optimization of targeted protein degraders
• This platform is enabling the selective degradation of pathways implicated in multiple diseases